Publications and presentations
Trial results
ATHENA has not reported yet. Primary results will be posted here and on ClinicalTrials.gov, and de-identified data will be deposited with the NHLBI BioLINCC repository.
Background science
Peer-reviewed work that led to this trial.
Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling
Nickel NP, Spiekerkoetter E, Gu M, et al. — Am J Respir Crit Care Med, 2015
Endogenous retroviral elements generate pathologic neutrophils in pulmonary arterial hypertension
Taylor S, Isobe S, Cao A, et al. — Am J Respir Crit Care Med, 2022
Severe pulmonary arterial hypertension is characterized by increased neutrophil elastase and relative elafin deficiency
Sweatt AJ, Miyagawa K, Rhodes CJ, et al. — Chest, 2021
Single-cell imaging maps inflammatory cell subsets to pulmonary arterial hypertension vasculopathy
Ferrian S, McCaffrey EF, Saito T, et al. — Am J Respir Crit Care Med, 2024